Literature DB >> 22566609

Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease.

Einat B Vitner1, Tamar Farfel-Becker, Raya Eilam, Inbal Biton, Anthony H Futerman.   

Abstract

Gaucher's disease, the most common lysosomal storage disorder, is caused by the defective activity of glucocerebrosidase, the lysosomal hydrolase that degrades glucosylceramide. The neuronopathic forms of Gaucher's disease are characterized by severe neuronal loss, astrocytosis and microglial proliferation, but the cellular and molecular pathways causing these changes are not known. In the current study, we delineate the role of neuroinflammation in the pathogenesis of neuronopathic Gaucher's disease and show significant changes in levels of inflammatory mediators in the brain of a neuronopathic Gaucher's disease mouse model. Levels of messenger RNA expression of interleukin -1β, tumour necrosis factor-α, tumour necrosis factor-α receptor, macrophage colony-stimulating factor and transforming growth factor-β were elevated by up to ∼30-fold, with the time-course of the increase correlating with the progression of disease severity. The most significant elevation was detected for the chemokines CCL2, CCL3 and CCL5. Blood-brain barrier disruption was also evident in mice with neuronopathic Gaucher's disease. Finally, extensive elevation of nitrotyrosine, a hallmark of peroxynitrite (ONOO(-)) formation, was observed, consistent with oxidative damage caused by macrophage/microglia activation. Together, our results suggest a cytotoxic role for activated microglia in neuronopathic Gaucher's disease. We suggest that once a critical threshold of glucosylceramide storage is reached in neurons, a signalling cascade is triggered that activates microglia, which in turn releases inflammatory cytokines that amplify the inflammatory response, contributing to neuronal death.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22566609     DOI: 10.1093/brain/aws095

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  53 in total

1.  Neuroinflammation, mitochondrial defects and neurodegeneration in mucopolysaccharidosis III type C mouse model.

Authors:  Carla Martins; Helena Hůlková; Larbi Dridi; Virginie Dormoy-Raclet; Lubov Grigoryeva; Yoo Choi; Alexander Langford-Smith; Fiona L Wilkinson; Kazuhiro Ohmi; Graziella DiCristo; Edith Hamel; Jerôme Ausseil; David Cheillan; Alain Moreau; Eva Svobodová; Zuzana Hájková; Markéta Tesařová; Hana Hansíková; Brian W Bigger; Martin Hrebícek; Alexey V Pshezhetsky
Journal:  Brain       Date:  2015-01-06       Impact factor: 13.501

Review 2.  Astrocytes and lysosomal storage diseases.

Authors:  K V Rama Rao; T Kielian
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

Review 3.  Immunologic privilege in the central nervous system and the blood-brain barrier.

Authors:  Leslie L Muldoon; Jorge I Alvarez; David J Begley; Ruben J Boado; Gregory J Del Zoppo; Nancy D Doolittle; Britta Engelhardt; John M Hallenbeck; Russell R Lonser; John R Ohlfest; Alexandre Prat; Maurizio Scarpa; Richard J Smeyne; Lester R Drewes; Edward A Neuwelt
Journal:  J Cereb Blood Flow Metab       Date:  2012-10-17       Impact factor: 6.200

Review 4.  Blood-brain barrier structure and function and the challenges for CNS drug delivery.

Authors:  N Joan Abbott
Journal:  J Inherit Metab Dis       Date:  2013-04-23       Impact factor: 4.982

Review 5.  Spotlights on immunological effects of reactive nitrogen species: When inflammation says nitric oxide.

Authors:  Andrea Predonzani; Bianca Calì; Andrielly Hr Agnellini; Barbara Molon
Journal:  World J Exp Med       Date:  2015-05-20

Review 6.  Monocyte chemoattractant protein-1 and the blood-brain barrier.

Authors:  Yao Yao; Stella E Tsirka
Journal:  Cell Mol Life Sci       Date:  2013-09-20       Impact factor: 9.261

7.  Anti-inflammatory Therapy With Simvastatin Improves Neuroinflammation and CNS Function in a Mouse Model of Metachromatic Leukodystrophy.

Authors:  Axel Stein; Stijn Stroobants; Volkmar Gieselmann; Rudi D'Hooge; Ulrich Matzner
Journal:  Mol Ther       Date:  2015-04-21       Impact factor: 11.454

Review 8.  Lysosomal storage diseases.

Authors:  Frances M Platt; Alessandra d'Azzo; Beverly L Davidson; Elizabeth F Neufeld; Cynthia J Tifft
Journal:  Nat Rev Dis Primers       Date:  2018-10-01       Impact factor: 52.329

9.  Self-Complementary AAV9 Gene Delivery Partially Corrects Pathology Associated with Juvenile Neuronal Ceroid Lipofuscinosis (CLN3).

Authors:  Megan E Bosch; Amy Aldrich; Rachel Fallet; Jessica Odvody; Maria Burkovetskaya; Kaitlyn Schuberth; Julie A Fitzgerald; Kevin D Foust; Tammy Kielian
Journal:  J Neurosci       Date:  2016-09-14       Impact factor: 6.167

10.  Transcriptomics of cortical gray matter thickness decline during normal aging.

Authors:  P Kochunov; J Charlesworth; A Winkler; L E Hong; T E Nichols; J E Curran; E Sprooten; N Jahanshad; P M Thompson; M P Johnson; J W Kent; B A Landman; B Mitchell; S A Cole; T D Dyer; E K Moses; H H H Goring; L Almasy; R Duggirala; R L Olvera; D C Glahn; J Blangero
Journal:  Neuroimage       Date:  2013-05-24       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.